<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074074</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-06023</org_study_id>
    <secondary_id>EORTC-06023</secondary_id>
    <nct_id>NCT00074074</nct_id>
  </id_info>
  <brief_title>Infliximab in Treating Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>Randomized Phase II Trial With Infliximab (Remicade) in Patients With Myelodysplastic Syndrome and a Relatively Low Risk of Developing Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as infliximab, can locate tumor cells and either kill
      them or deliver tumor-killing substances to them without harming normal cells.

      PURPOSE: Randomized phase II trial to study the effectiveness of infliximab in treating
      patients who have myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the therapeutic activity of 2 different doses of infliximab on peripheral
           blood cell count and peripheral and bone marrow blast cell count in patients with low-
           or intermediate-risk myelodysplastic syndromes.

        -  Determine the subjective and objective toxicity of these regimens in these patients.

        -  Determine the response rates (complete and partial response and hematological
           improvement) in patients treated with these regimens.

        -  Determine the duration of response in patients treated with these regimens.

      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
      according to cytogenetics (good vs intermediate vs unknown due to failure), overall
      International Prognostic Scoring System score (low [0] vs intermediate 1 [0.5-1.0] vs
      intermediate 2 [1.5-2.0]), and participating center. Patients are randomized to 1 of 2
      treatment arms.

        -  Arm I: Patients receive infliximab IV on days 1, 15, 43, 71, 99, 127, 155, and 183 in
           the absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients receive a higher dose of infliximab as in arm I. Patients achieving
           response (complete or partial response or hematological improvement) continue therapy
           beyond day 183 in the absence of disease progression.

      Patients are followed at 2 weeks and then every 3 months thereafter.

      PROJECTED ACCRUAL: A total of 80 patients (40 per treatment arm) will be accrued for this
      study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best response as measured by Cheson response criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of highest grade toxicity as assessed by CTCAE v3.0 after response</measure>
  </secondary_outcome>
  <enrollment type="Actual">46</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>infliximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Confirmed diagnosis (within the past month) of low- or intermediate-risk
             myelodysplastic syndromes (MDS) meeting all of the following criteria:

               -  No more than 10% bone marrow blasts (corresponding to refractory anemia [RA], RA
                  with ringed sideroblasts, or RA with excess blasts)

               -  Meets at least 1 of the following hematopoietic criteria:

                    -  Hemoglobin no greater than 10 g/dL OR red blood cell transfusion dependent

                    -  Neutrophil count no greater than 1,500/mm^3

                    -  Platelet count no greater than 100,000/mm^3 OR platelet transfusion
                       dependent

               -  No poor cytogenetics (complex abnormalities or involvement of chromosome 7)

                    -  Patients with unknown cytogenetics may be eligible provided reasonable
                       efforts have been made for determining the cytogenetic profile and the
                       results are considered a failure (e.g., normal karyotype [NN] with no more
                       than 10 metaphases)

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  WHO 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  No history of documented hepatitis C

          -  No documented active hepatitis B

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  ALT less than 2.5 times ULN

        Renal

          -  Creatinine less than 1.5 times ULN

        Cardiovascular

          -  No New York Heart Association class III or IV heart disease

          -  No clinical history or evidence of congestive heart failure

          -  No severe cardiac dysfunction

          -  LVEF greater than 35%

        Pulmonary

          -  No prior or concurrent active or latent tuberculosis (TB)

               -  No evidence of prior or concurrent active TB (i.e., fibrotic or pleural scarring,
                  pulmonary nodules, mediastinal and/or hilar lymphadenopathy, upper lobe volume
                  loss, or cavitation) by chest x-ray

               -  Negative intradermal tuberculin skin test (i.e., induration less than 5 mm)

          -  No severe pulmonary dysfunction

        Immunologic

          -  No prior or concurrent opportunistic infection (e.g., herpes zoster, cytomegalovirus,
             Pneumocystic carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB)
             within the past 6 months

          -  No concurrent severe (CTC grade III or IV) active, chronic, or recurrent infections

          -  No recent history of allergies

          -  HIV negative

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after study
             participation

          -  No prior clinically significant adverse event to murine or chimeric proteins or
             human/murine recombinant products

          -  No recent contact with an individual with active TB

          -  No poor medical risk due to other systemic disease

          -  No multiple sclerosis or other demyelinating disorder

          -  No peripheral neuropathy greater than CTC grade 1

          -  No other malignancy within the past 5 years except adequately treated carcinoma in
             situ of the cervix or nonmelanoma skin cancer

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior infliximab or other monoclonal antibodies

          -  At least 6 weeks since prior hematopoietic growth factors for MDS

          -  At least 3 months since prior therapy targeted at reducing tumor necrosis factor (TNF)
             alpha (e.g., pentoxifylline, thalidomide, or etanercept)

          -  No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)

          -  No other concurrent drugs targeted at reducing TNF alpha (e.g., pentoxifylline,
             thalidomide, or etanercept)

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  No prior solid organ transplantation

               -  Corneal transplantation more than 3 months ago allowed

        Other

          -  No prior randomization to this clinical trial

          -  At least 6 weeks since prior treatment for MDS (except supportive care)

          -  No other concurrent investigational agents

          -  No other concurrent anticancer therapy

          -  No concurrent therapeutic-dose nonsteroidal anti-inflammatory drugs (NSAIDs)

               -  Concurrent sporadic (no more than 3 tablets/week) over-the-counter NSAIDs allowed

          -  Concurrent cardioprotective doses (80 mg/day or equivalent) of aspirin allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Zwierzina, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University Innsbruck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Hartziekenhuis - Roeselaere.</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>B-4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Prague</city>
        <zip>128 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruprecht - Karls - Universitaet Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest German Cancer Center at Eberhard-Karls-University</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <zip>I-61100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Bronovo</name>
      <address>
        <city>Den Haag</city>
        <zip>2597AX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Baron F, Suciu S, Amadori S, Muus P, Zwierzina H, Denzlinger C, Delforge M, Thyss A, Selleslag D, Indrak K, Ossenkoppele G, de Witte T. Value of infliximab (RemicadeÂ®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica. 2012 Apr;97(4):529-33. doi: 10.3324/haematol.2011.044347. Epub 2011 Nov 18.</citation>
    <PMID>22102701</PMID>
  </results_reference>
  <results_reference>
    <citation>Baila L, Suciu S, Muus P, et al.: Assessment of two doses of infliximab in patients with low/intermediate risk IPSS myelodysplastic syndrome (MDS): an EORTC leukemia group (LG) randomized phase II trial (06023). [Abstract] Blood 110 (11): A-1456, 2007.</citation>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

